Spire Health has launched a research study on COPD exacerbations using continuous respiratory sensors to assess adherence and identify digital biomarkers preceding exacerbations.
AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
AstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in chronic obstructive pulmonary disease (COPD) failed to match the pe
NICE has published draft guidance restricting use of antibiotics in patients with chronic obstructive pulmonary disease (COPD), as in many cases the treatment is inappropriate and could lea
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl